展望
CGRP及其受体的抗体是目前最优的预防偏头痛的在研药物,上市几无悬念,最早可能在2018年上市,有可能成为半个世纪以来偏头痛治疗首个新机理药物。目前四个候选药物均有多项临床试验正在进行中,竞争白热化,Evaluate Pharma预测2020年该类抗体销售额将超过25亿美元。另外,CGRP有可能成为偏头痛的生物标志物,有望开启偏头痛的精准治疗时代,目前礼来已经登记了该项临床试验。
考虑到临床疗效、患者顺应性以及药物经济性,就像Alder所宣称的那样,ALD403可能最晚上市但可能成为同类最优药物。CGRP抗体是迄今为止唯一一个专门针对预防性治疗慢性偏头痛而设计的药物,有望打破Botox在该适应症的垄断地位,为患者提供更加优秀的药物。药物的设计、生产、临床使用及病人细分等方面的差异化都可能成为开发同类最优药物的钥匙,值得仔细思考。
参考文献
[1] 中国偏头痛诊断治疗指南(2011年). [2] CGRPreceptor antagonists andantibodies against CGRP and its receptor in migrainetreatment (2015). [3] Newtherapeutic approaches for the prevention and treatment of migraine (2015). [4] Therapeuticantibodies against CGRP or its receptor (2014). [5] TherapeuticMonoclonalAntibodies-What Headache Specialists Need to Know (2015). [6] Update onthe Pharmacological Treatment of Chronic Migraine (2016). [7] CGRP andMigraine Current Understanding and State of Development(2013). [8] TEV-48125:a Review of a Monoclonal CGRPAntibody in Development for the Preventive Treatment of Migraine (2015). [9] TEV-48125for the preventive treatment of chronic migraine Efficacy at early time points(2016). [10] Safety,tolerability, and efficacy of TEV-48125 for preventive treatment of chronicmigraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2bstudy (2015). [11] Safety,tolerability, and efficacy of TEV-48125 for preventive treatment ofhigh-frequency episodic migraine: a multicentre, randomised, double-blind,placebo-controlled, phase 2b study (2015). [12] Safetyand efficacy of ALD403, an antibody to calcitonin gene-related peptide, for theprevention of frequent episodic migraine: a randomised, double-blind,placebo-controlled, exploratory phase 2 trial (2014). [13] 各公司及CFDA、FDA、Labiotech、clinicaltrials官网。 [14] Theprevalence and burden of primary headaches in China: a population-baseddoor-to-door survey (2012).
|